Stock Events

Stock Events

Search...

Immunovant

$24.8

57

+$0.7+2.9% Today

Statistics

Day High

24.8

Day Low

24.1

52W High

-

52W Low

-

Volume

156

Avg. Volume

-

Mkt Cap

5.05B

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

3JunExpected

Q3 2025

Q4 2025

Next

-0.73

-0.69

-0.64

-0.6

Expected EPS

-0.599452

Actual EPS

N/A

Financials

-Profit Margin

Unprofitable

2019

2020

2021

2022

2023

2024

0Revenue

-827.68MNet Income

Analyst Ratings

$35.80Average Price Target

The highest estimate is 50.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.

Buy

60%

Hold

40%

Sell

0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMVT.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

argenx competes directly with Immunovant in developing treatments for autoimmune diseases, specifically targeting the FcRn pathway similar to Immunovant's approach.

United Community Banks

UCB is involved in creating therapies for autoimmune and inflammatory diseases, competing in the same therapeutic areas as Immunovant.

AbbVie has a broad portfolio in immunology, including treatments for autoimmune diseases, making it a competitor in the same market as Immunovant.

Amgen's focus on novel therapeutics in inflammation and immunology positions it as a competitor to Immunovant in the autoimmune disease space.

GlaxoSmithKline has a diverse immunology pipeline that includes treatments for autoimmune diseases, competing with Immunovant's therapeutic focus.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, known for its innovative therapies in immunology, competes with Immunovant in developing treatments for autoimmune diseases.

Novartis has a strong presence in the immunology and dermatology space, making it a competitor to Immunovant in developing autoimmune disease treatments.

Bristol-Myers Squibb

Bristol Myers Squibb's extensive research in immune system modulation and autoimmune diseases places it as a competitor to Immunovant.

About

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Show more...

CEO

ISIN

US45258J1025

Listings

0 Comments

Share your thoughts

FAQ

What is Immunovant stock price today?▼

The current price of IMVT.BOATS is $24.8 USD — it has increased by +2.9% in the past 24 hours. Watch Immunovant stock price performance more closely on the chart.

What is Immunovant stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Immunovant stocks are traded under the ticker IMVT.BOATS.

What is Immunovant market cap?▼

Today Immunovant has the market capitalization of 5.05B

When is the next Immunovant earnings date?▼

Immunovant is going to release the next earnings report on June 03, 2026.

What were Immunovant earnings last quarter?▼

IMVT.BOATS earnings for the last quarter are -0.61 USD per share, whereas the estimation was -0.71 USD resulting in a +14.5% surprise. The estimated earnings for the next quarter are N/A USD per share.

What is Immunovant revenue for the last year?▼

Immunovant revenue for the last year amounts to 0 USD.

What is Immunovant net income for the last year?▼

IMVT.BOATS net income for the last year is -827.68M USD.

When did Immunovant complete a stock split?▼

Immunovant has not had any recent stock splits.